Insmed (INSM) Common Equity (2010 - 2026)
Insmed (INSM) posted quarterly Common Equity of $704.9 million for Q1 2026, up 610.83% year-over-year from $99.2 million in Q1 2025, and down 4.62% quarter-over-quarter from $739.0 million in Q4 2025.
Insmed (INSM) Common Equity (2010 - 2026) Analysis & Trends
Insmed's Common Equity history runs 17 years deep, the most recent figure standing at $704.9 million for Q1 2026.
- In Q1 2026, Common Equity rose 610.83% year-over-year to $704.9 million; the TTM figure through Mar 2026 stood at $704.9 million (up 610.83% YoY), while the FY2025 annual figure was $739.0 million, up 158.95% from the prior year.
- Common Equity for Q1 2026 stood at $704.9 million, down from $739.0 million in the prior quarter.
- The five-year high for Common Equity was $1.2 billion in Q2 2025, with the low at -$464.8 million in Q1 2024.
- The 5-year median for Common Equity is $88.0 million (2022), against an average of $204.8 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 940.93% in 2024, then surged 3119.47% in 2025.
- Insmed's Common Equity stood at $88.0 million in 2022, then plunged by 477.4% to -$331.9 million in 2023, then jumped by 185.98% to $285.4 million in 2024, then jumped by 158.95% to $739.0 million in 2025, then declined by 4.62% to $704.9 million in 2026.
- Business Quant data shows INSM's Common Equity at $704.9 million in Q1 2026, $739.0 million in Q4 2025, and $945.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 757.49 Mn |
| Mar 31, 2026 | 704.85 Mn |
| Dec 31, 2025 | 738.98 Mn |
| Sep 30, 2025 | 945.57 Mn |
| Jun 30, 2025 | 1.25 Bn |
| Mar 31, 2025 | 99.16 Mn |
| Dec 31, 2024 | 285.38 Mn |
| Sep 30, 2024 | 483.42 Mn |
| Jun 30, 2024 | 38.82 Mn |
| Mar 31, 2024 | -464.81 Mn |
| Dec 31, 2023 | -331.92 Mn |
| Sep 30, 2023 | -289.36 Mn |
| Jun 30, 2023 | -155.75 Mn |
| Mar 31, 2023 | -44.65 Mn |
| Dec 31, 2022 | 87.95 Mn |
| Sep 30, 2022 | -29.96 Mn |
| Jun 30, 2022 | 44.24 Mn |
| Mar 31, 2022 | 119.88 Mn |
| Dec 31, 2021 | 410.47 Mn |
| Sep 30, 2021 | 504.84 Mn |